These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21784141)

  • 1. European Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary--Formulating better medicines for children.
    Salunke S; Hempenstall J; Kendall R; Roger B; Mroz C; Nunn T; Tuleu C
    Int J Pharm; 2011 Oct; 419(1-2):235-9. PubMed ID: 21784141
    [No Abstract]   [Full Text] [Related]  

  • 2. European Paediatric Formulation Initiative (EuPFI) successfully navigating the road to formulating better medicines for children.
    Salunke S
    Eur J Pharm Biopharm; 2021 Oct; 167():114-115. PubMed ID: 34175374
    [No Abstract]   [Full Text] [Related]  

  • 3. European Paediatric Formulation Initiative (EuPFI)-Formulating Ideas for Better Medicines for Children.
    Salunke S; Liu F; Batchelor H; Walsh J; Turner R; Ju TR; Tuleu C;
    AAPS PharmSciTech; 2017 Feb; 18(2):257-262. PubMed ID: 27422653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future of the European Union regulatory network in the context of the uptake of new medicines.
    Hoebert JM; Irs A; Mantel-Teeuwisse AK; Leufkens HG
    Br J Clin Pharmacol; 2013 Jul; 76(1):1-6. PubMed ID: 23043328
    [No Abstract]   [Full Text] [Related]  

  • 5. Pediatric formulation issues identified in Paediatric Investigation Plans.
    Quijano Ruiz B; Desfontaine E; Arenas-López S; Wang S
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):25-30. PubMed ID: 24308789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conference report: formulating better medicines for children: 4th European Paediatric Formulation Initiative conference.
    Walsh J; Mills S
    Ther Deliv; 2013 Jan; 4(1):21-5. PubMed ID: 23323778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical Portfolio & Product Life Cycle Management--SMi's fourth annual conference. 29-30 June 2009, London, UK.
    Beecher N
    IDrugs; 2009 Sep; 12(9):558-60. PubMed ID: 19697274
    [No Abstract]   [Full Text] [Related]  

  • 8. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude.
    Ehmann F; Papaluca Amati M; Salmonson T; Posch M; Vamvakas S; Hemmings R; Eichler HG; Schneider CK
    Clin Pharmacol Ther; 2013 May; 93(5):425-32. PubMed ID: 23549149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meeting commentary--formulating better medicines for children.
    Hempenstall J; Tuleu C
    Int J Pharm; 2009 Sep; 379(1):143-5. PubMed ID: 19576979
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
    Winzenburg G
    Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug control within the EEC I: coordination during the 1990's].
    Strandberg K
    Lakartidningen; 1992 Jan; 89(3):100-1. PubMed ID: 1734132
    [No Abstract]   [Full Text] [Related]  

  • 16. [EURO-Medicines: a European program for bringing into agreement public health policies on drugs].
    Calamo-Specchia F; Bucci R; Folino-Gallo P
    Ann Ig; 1998; 10(5-6):405-12. PubMed ID: 10052204
    [No Abstract]   [Full Text] [Related]  

  • 17. EU offers incentives to firms to produce medicines for children.
    Watson R
    BMJ; 2006 Jun; 332(7554):1352. PubMed ID: 16763236
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad.
    Croft DE; Wykoff CC; Michels S; Chakravarthy U; Cruess AF
    Am J Ophthalmol; 2016 Sep; 169():xiv-xvi. PubMed ID: 27485923
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationale drug therapy: reasons for failure and suggestions for its implementation.
    Mathur GP; Kushwaha KP; Mathur S
    Indian Pediatr; 1993 Jun; 30(6):815-8. PubMed ID: 7726879
    [No Abstract]   [Full Text] [Related]  

  • 20. Value for money of drug regulation.
    Bouvy JC; Koopmanschap MA; Schellekens H
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):247-9. PubMed ID: 22812545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.